Claims for Patent: 7,300,919

Summary for Patent: 7,300,919

Title:	Pulmonary delivery of active fragments of parathyroid hormone
Abstract:	Systemic delivery of parathyroid hormone to a mammalian host is accomplished by inhalation through the mouth of a dispersion of an N-terminal fragment of PTH. It has been found that such respiratory delivery of the PTH fragment provides a pulsatile concentration profile of the PTH in the host\'s serum. PTH fragment compositions include dry powder formulations having the PTH present in a dry bulking powder, liquid solutions or suspensions suitable for nebulization, and aerosol propellants suitable for use in a metered dose inhaler.
Inventor(s):	Patton; John S. (San Carlos, CA)
Assignee:	Nektar Therapeutics (San Carlos, CA)
Application Number:	10/245,707
Patent Claims:	1. A therapeutic composition in solid dose form comprising a bulking agent and an N-terminal peptide fragment of parathyroid hormone (PTH) as a bioactive agent, wherein said composition is a powder suitable for administration by inhalation, said bulking agent is selected from the group consisting of sucrose, lactose, trehalose, dextran and maltotriose, and said powder has a particle size between 0.5 .mu.m to 5 .mu.m. 2. The composition according to claim 1, wherein said peptide fragment consists of the first 34 amino acids of SEQ ID NO: 1. 3. The composition according to claim 1, wherein said peptide fragment consists of the first 34 to 38 amino acids of SEQ ID NO: 1. 4. The composition according to claim 1, further comprising an additive to maintain or enhance chemical stability and physiological acceptability. 5. The composition according to claim 4, wherein the additive is a peptidase inhibitor. 6. The composition according to claim 4, wherein the additive is a chelating agent.

Details for Patent 7,300,919

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2012-09-29